Replies to post #219357 on Innovation Pharmaceuticals Inc (IPIX)

[farrell90]

Reading your post made may go back and compare the Brillacidin OM data with Galera's GC4419.

I agree with your assessment it is hard to compare since neither company gave us all the raw data and the summary of the data focused on different aspects of the studies.

One area both companies reported was the reduction of incidence.

Galera reported the reduction of incidence of OM with GC4419 to be 34 %

IPIX did report raw data for the reduction of incidence.

In the mTT group 42.9/60 or a 28% reduction
In the PP group 36.8/60 or a 39% reduction

The reduction of incidence of OM is similar in both studies regarding the reduction of incidence with the respective treatments. The p values would be similar in these small studies.

Good luck, Farrell